Intec Pharma shares dive after Parkinson's trial failure

Intec Pharma’s Parkinson’s gradual release disease drug trial has missed its primary endpoint, causing the biotech’s share price to crash.

AI specialist Exscientia forms rare disease JV with RallyBio

ViiV’s first-in-class HIV drug on course for filings this ye...

Broad, MilliporeSigma issue call to make access to CRISPR fr...

Genentech extends small-molecule R&D with three platform dea...

Boehringer announces IPF deal with Korea's Bridge Biotherape...

Boehringer Ingelheim and South Korean biotech Bridge Biotherapeutics have announced a deal to develop the latter’s drug for idiopathic pulmonary fibrosis (IPF).